October 29, 2025

Company name:	FINDEX Inc.
Name of representative:	Teruo Aibara, President & CEO (Securities code: 3649; PRIME Market)
Inquiries:	Takashi Murakami, Finance & Investor Relations, Business Strategy (Telephone: +81-3-6271-8958)

Notice Regarding the Establishment of the "Medical Data Platform Business"

FINDEX Inc. ("The Company"), hereby announces that, as of September 30, 2025, the Company has been certified by the Cabinet Office of Japan as a "Certified Medical Information Handling Business Operator" under the Next-Generation Medical Infrastructure Act. Based on this certification, the Company resolved at its Board of Directors meeting today to establish the "Medical Data Platform Business" within its existing Health Tech Business segment and officially launch the business on November 1, 2025.

For the press release regarding this certification, please refer to the following:
https://findex.co.jp/en/newsrelease/2025/en_news_251001.html

1. Background and Purpose of the Medical Data Platform Business

Due to privacy protection requirements, the utilization of clinical data from medical institutions had long been subject to strict limitations, preventing active secondary use of such data. However, recent legal reforms and technological advancements have enabled the secure use of electronic medical record data, ushering in a new phase of medical data utilization in Japan.

Until now, medical data analysis has centered on claims and check-up data. Going forward, however, research and development will increasingly leverage more value-added datasets that reflect real-world clinical practice, including patients' test results, treatment and prescription records, and symptom progression. This is expected to accelerate initiatives that enhance the sustainability of the medical industry—such as expanding drug discovery opportunities, streamlining clinical trials, optimizing regional healthcare systems, and improving medical access.

Since its founding, Findex has been deeply involved in building medical information infrastructure for medical institutions, including the development of electronic medical records, image management systems, medical information sharing networks, and e-prescription platforms. In addition, through projects such as the analysis of visual field data using its own ophthalmic medical devices and early detection of MCI (Mild Cognitive Impairment), the company has developed advanced expertise and practical capabilities in medical data utilization over many years.

This certification represents a major step forward, positioning Findex not only as a system and medical device vendor but as an officially certified organization that will play a central role in advancing medical data utilization in Japan. Building on its track record in data analysis and utilization within the health tech domain, the company is establishing this new business to further contribute to the medical industry and public health through the promotion of advanced data utilization.

2. Overview of the Medical Data Platform Business

Clinical data held by medical institutions is among the most precise and valuable forms of medical information, and its use carries significant potential for societal impact.

Through the Medical Data Platform Business, Findex will collect and integrate clinical data after pseudonymization and anonymization to ensure security, and provide an environment where research institutions, private companies, and government and municipal bodies can utilize the data for drug development, medical research, and policy planning.

3. Future Outlook

Going forward, Findex aims to integrate its existing medical business with the Medical Data Platform Business, a new pillar within its health tech segment, to evolve into a comprehensive medical data company that manages and utilizes medical information end-to-end.

Through this initiative, the company intends to deliver medical data utilization infrastructure to society and further strengthen its position as a leading company in the medical information field.

Although the impact of this initiative on the company’s performance for the current fiscal year is expected to be minimal, it is expected to make a significant contribution to enhancing corporate value over the medium to long term. Any further developments subject to disclosure will be announced promptly.